Adlai Nortye (ANL) Competitors $1.50 +0.05 (+3.45%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$1.51 +0.01 (+0.60%) As of 08/4/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ANL vs. CGC, CRGX, FDMT, NLTX, DMAC, EPRX, GALT, GNFT, IPHA, and LYELShould you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Canopy Growth (CGC), CARGO Therapeutics (CRGX), 4D Molecular Therapeutics (FDMT), Neoleukin Therapeutics (NLTX), DiaMedica Therapeutics (DMAC), Eupraxia Pharmaceuticals (EPRX), Galectin Therapeutics (GALT), GENFIT (GNFT), Innate Pharma (IPHA), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. Adlai Nortye vs. Its Competitors Canopy Growth CARGO Therapeutics 4D Molecular Therapeutics Neoleukin Therapeutics DiaMedica Therapeutics Eupraxia Pharmaceuticals Galectin Therapeutics GENFIT Innate Pharma Lyell Immunopharma Adlai Nortye (NASDAQ:ANL) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk. Which has more volatility and risk, ANL or CGC? Adlai Nortye has a beta of -0.95, meaning that its share price is 195% less volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Which has better earnings and valuation, ANL or CGC? Adlai Nortye has higher earnings, but lower revenue than Canopy Growth. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai Nortye$5M11.07-$51.87MN/AN/ACanopy Growth$225.65M1.00-$429.86M-$4.04-0.27 Do analysts recommend ANL or CGC? Adlai Nortye currently has a consensus target price of $9.00, suggesting a potential upside of 500.00%. Given Adlai Nortye's stronger consensus rating and higher possible upside, analysts plainly believe Adlai Nortye is more favorable than Canopy Growth.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Canopy Growth 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media prefer ANL or CGC? In the previous week, Canopy Growth had 4 more articles in the media than Adlai Nortye. MarketBeat recorded 4 mentions for Canopy Growth and 0 mentions for Adlai Nortye. Canopy Growth's average media sentiment score of 0.59 beat Adlai Nortye's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media. Company Overall Sentiment Adlai Nortye Neutral Canopy Growth Positive Do institutionals and insiders hold more shares of ANL or CGC? 35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 3.3% of Canopy Growth shares are held by institutional investors. 1.3% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is ANL or CGC more profitable? Adlai Nortye has a net margin of 0.00% compared to Canopy Growth's net margin of -195.76%. Adlai Nortye's return on equity of 0.00% beat Canopy Growth's return on equity.Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A Canopy Growth -195.76%-88.54%-40.78% SummaryAdlai Nortye beats Canopy Growth on 8 of the 13 factors compared between the two stocks. Get Adlai Nortye News Delivered to You Automatically Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANL vs. The Competition Export to ExcelMetricAdlai NortyeMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.51M$3.02B$5.51B$9.35BDividend YieldN/A2.46%4.74%4.15%P/E RatioN/A18.0629.1424.41Price / Sales11.07272.71435.00101.03Price / CashN/A40.5624.4827.20Price / Book2.178.628.525.77Net Income-$51.87M-$54.98M$3.24B$264.99M7 Day Performance5.01%-0.87%0.65%-0.68%1 Month Performance-4.21%16.08%7.97%7.08%1 Year Performance-51.30%14.18%30.98%23.80% Adlai Nortye Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANLAdlai Nortye1.7678 of 5 stars$1.50+3.4%$9.00+500.0%-54.7%$53.51M$5M0.00127Upcoming EarningsGap UpCGCCanopy Growth0.5641 of 5 stars$1.03-6.0%N/A-83.3%$210.28M$269.00M-0.253,150Upcoming EarningsCRGXCARGO Therapeutics2.3089 of 5 stars$4.50-0.1%$15.40+242.6%-71.3%$207.26MN/A-0.97116Upcoming EarningsFDMT4D Molecular Therapeutics2.5433 of 5 stars$4.41-4.9%$29.56+570.0%-67.4%$204.29M$23K-1.39120News CoverageUpcoming EarningsGap DownNLTXNeoleukin TherapeuticsN/A$21.68-4.6%N/A-44.9%$203.75MN/A-6.9790Gap DownDMACDiaMedica Therapeutics1.2241 of 5 stars$4.69-7.4%$10.75+129.5%+31.7%$202.18MN/A-7.3720Positive NewsUpcoming EarningsEPRXEupraxia Pharmaceuticals2.8002 of 5 stars$5.61-1.0%$11.00+96.0%+108.8%$201.76MN/A-7.3829Upcoming EarningsGALTGalectin Therapeutics2.7216 of 5 stars$3.18+3.8%$6.00+89.0%+62.1%$200.95MN/A-4.419Upcoming EarningsGNFTGENFIT1.5775 of 5 stars$4.01-3.6%$13.00+224.2%-5.7%$200.50M$76.77M0.00120IPHAInnate Pharma2.3526 of 5 stars$2.14-2.7%$11.00+414.0%-1.6%$197.27M$12.62M0.00220Positive NewsGap UpLYELLyell Immunopharma2.9662 of 5 stars$13.25-3.5%$15.00+13.2%-61.8%$196.83M$60K-0.53270Upcoming Earnings Related Companies and Tools Related Companies Canopy Growth Alternatives CARGO Therapeutics Alternatives 4D Molecular Therapeutics Alternatives Neoleukin Therapeutics Alternatives DiaMedica Therapeutics Alternatives Eupraxia Pharmaceuticals Alternatives Galectin Therapeutics Alternatives GENFIT Alternatives Innate Pharma Alternatives Lyell Immunopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANL) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANL Stock Alerts